Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "DASATINIB TABLET" PASSES CONSISTENCY EVALUATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"DASATINIB TABLET" PASSES CONSISTENCY EVALUATION

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company", together with its subsidiaries, the "Group") announces that "Dasatinib Tablet" (product name: Yinishu (依尼 舒)) (specifications: 20mg and 50mg), an oncology medicine developed by the Group, has obtained the notice of approval of supplemental application on pharmaceutical product issued by the National Medical Products Administration of the People's Republic of China, and passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs ("Consistency Evaluation"). This product is used for the treatment of adult patients with Philadelphia Chromosome positive (Ph +) chronic myelogenous leukemia ("CML") in chronic phase, accelerated phase and blast phase (acute granular change and blastic change) who are resistant or intolerant to imatinib mesylate.

CML is a malignant proliferative disease arising from multifunctional hematopoietic stem cells. Experiment results indicate that BCR-ABL tyrosine kinase is currently the best target for molecular targeted therapy against leukemia. As a second-generation tyrosine kinase inhibitor, dasatinib can overcome imatinib resistance with higher effectiveness on BCR-ABL positive cell line inhibition and BCR-ABL phosphorylation reduction compared with imatinib, thus gradually strengthening its presence in first-line and second-line treatment of CML.

The production and sales volume of Yinishu have been increasing year by year since its launch in 2013. Passing the Consistency Evaluation, Yinishu is recognized as an alternative to the imported pharmaceutical preparation, providing clinicians with another solid choice for the treatment of leukemia.

1

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 12 May 2021

As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five Independent Non- Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Mr. Li Kwok Tung Donald.

2